Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/cid/cix803 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Article Synopsis
- Recent research has classified a specific bacterial strain as low-risk for producing a certain enzyme affecting antibiotic efficacy, but there is limited data on how antibiotic choices impact patient outcomes in bacteremia.
- This study focused on comparing clinical outcomes between patients treated with AmpC-directed β-lactam therapy and narrower spectrum therapies for ceftriaxone-susceptible bacteremia, reviewing records over an 8-year period from seven hospitals.
- Results indicated that while carbapenem therapy showed trends toward lower mortality and longer treatment duration, these differences weren't statistically significant, emphasizing the need for proper antibiotic stewardship to avoid the development of drug-resistant bacteria.
Effectiveness of traditional non-carbapenem β-lactams vs. novel β-lactams for the treatment of carbapenem-resistant Pseudomonas aeruginosa: a retrospective cohort study.
BMC Infect Dis
December 2024
Clinical Pharmacy Department, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Background: The World Health Organization (WHO) has identified carbapenem-resistant Pseudomonas aeruginosa (CRPA) as one of the three critical priority pathogens. There is scarce literature evaluating the treatment outcomes in patients with CRPA infections treated with traditional non-carbapenem β-lactam (NCBL) agents. Thus, this study aims to assess the effectiveness of traditional NCBL compared to novel β-lactam agents (NVL) for treating non-carbapenem β-lactam -susceptible CRPA.
View Article and Find Full Text PDFEvaluation of risk factors for 14-day and 30-day mortality among treatment regimens against Pseudomonas aeruginosa resistant to carbapenem but susceptible to traditional antipseudomonal non-carbapenem β-lactam agents.
PLoS One
November 2024
Department of Pharmaceutical Care, Faculty of Pharmacy, Silpakorn University, Nakorn Pathom, Thailand.
Pseudomonas aeruginosa associated with hospital-acquired infection is often resistant to various antibiotics and is associated with high mortality worldwide. The appropriate treatment of Pseudomonas aeruginosa resistant to carbapenems but susceptible to traditional antipseudomonal non-carbapenem β-lactam agents (Car-R/NonCar-S P. aeruginosa) remains unclear.
View Article and Find Full Text PDFClinical Outcomes of Patients with AmpC-Beta-Lactamase-Producing Enterobacterales Bacteremia Treated with Carbapenems versus Non-Carbapenem Regimens: A Single-Center Study.
Antibiotics (Basel)
July 2024
Faculty of Medicine, Hebrew University, Jerusalem 91904, Israel.
Introduction: Bloodstream infections caused by AmpC-producing Enterobacterales pose treatment challenges due to the risk of AmpC overproduction and treatment failure. Current guidelines recommend carbapenems or cefepime as optimal therapy. We aimed to evaluate empiric and definitive non-carbapenem regimens for these infections.
View Article and Find Full Text PDFCarbapenem Versus Non-carbapenem Therapy in Hematology Patients: Extended-Spectrum Beta-Lactamase Positive Enterobacteriaceae Colonization Impact.
Cureus
July 2024
Infectious Diseases and Clinical Microbiology Clinic, Antalya Education and Research Hospital, Antalya, TUR.
Article Synopsis
- Extended-spectrum beta-lactamase-producing (ESBL-E) infections significantly impact patients with hematologic cancers, particularly those with prior colonization by resistant bacteria, leading to optimized treatments using carbapenems.
- A study comparing empirical carbapenem therapy to non-carbapenem therapy in hospitalized adult hematology patients showed that 36% had positive ESBL-E colonization, yet the rate of future infections did not significantly differ between colonized and non-colonized patients.
- Despite the presence of ESBL-E, there were no significant mortality rates associated with these infections, indicating that factors beyond colonization status may influence patient outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!